Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Date:11/8/2007

velop, manufacture, license and sell its

products or product candidates;

* the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

* the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

* the adequacy of the Company's patents and proprietary rights;

* the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

* the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

* the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

Brian Korb

The Trout Group

908-286-3980

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics including high value and difficult ... follow-on public offering of 6,000,000 shares of its common ... per share. Of the shares being offered, 2,610,000 are ... are being offered by existing stockholders. Pfenex will not ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of its ... lighting market. In recent months, there have ... emerging markets such as Russia, South America, and ... such as streetlight and area lighting, tunnel lighting, ... in 2005 the Acrich technology from Seoul Semiconductor ...
(Date:4/23/2015)... 23, 2015 /CNW/ - A new and innovative service ... North America,s largest packaging ... Silver in the "Sustainability, service" category of the ... "Competitor Comparison" is a service that scores clients, ... Global peers. This benchmarking process shows clients how ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... AUXL ) today announced that executive management will ... held June 4-7, 2012 at the Grand Hyatt in New ... is scheduled to present an overview of the Company and ... 4, 2012. A breakout session will be held following the ...
... PARSIPPANY, N.J., May 29, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... company, announced today that Paul Bisaro, Watson,s President and ... of the Company,s business at the Goldman Sachs Global ... 8:00AM Pacific Time at the Terranea Resort in Rancho ...
... conditions such as multiple sclerosis and heart and liver ... and life sciences facilities opened yesterday by HRH, the ... unveil plaques this afternoon at the $85 million Scottish ... facility, Nine, in Edinburgh. The University of ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 2Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 3Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 4Watson to Present at Goldman Sachs Global Healthcare Conference 2012 2Scotland opens stem cell research center and bio-medical incubator 2
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Hackensack, NJ (June 29, 2011) Researchers at the John ... of social support to distress after stem cell transplants. Scott ... the John Theurer Cancer Center at Hackensack University Medical Center ... Labay from Mt. Sinai. The study was published in the ...
... CORPUS CHRISTI Just as corn and ... discovered multi-beneficial uses and applications, Texas AgriLife Research scientists ... "It,s a huge, untapped source of fuel, food, ... a crop physiologist at the Texas AgriLife Research and ...
... rebirth, but if it comes too early, it can threaten ... of Alberta study shows that climate change over the past ... and trees into earlier blooming times, making them more vulnerable ... of A PhD candidate Elisabeth Beaubien and her supervisor, professor ...
Cached Biology News:John Theurer Cancer Center BMT researchers highlight the importance of social support 2Microalgae could be Texas' next big cash crop 2Microalgae could be Texas' next big cash crop 3
... Immunogen: Synthetic phosphopeptide corresponding to ... Ser603 residue of rat Synapsin ... synapsin I when phosphorylated at ... Rat (positive control: rat brain ...
EMBP (FL-222)...
... PhosphatidylEthanolamine-Binding Protein (PEBP) does not share ... inhibitors. PEBP is expressed in ... ovary, muscle, and stomach. One ... is exerting inhibitory activity against several ...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: